Incidence of Nd:YAG laser capsulotomy following cataract surgery: a population-based nation-wide study – FreYAG1 study

Author:

Brézin Antoine P.,Labbe Antoine,Schweitzer Cédric,Lignereux François,Rozot Pascal,Goguillot Mélanie,Bugnard Françoise,Dot Corinne

Abstract

Abstract Rationale Nd:YAG (neodymium:yttrium-aluminum-garnet) capsulotomy (Nd:YAG-caps) is the gold standard for the treatment of PCO (Posterior Capsule Opacification). There is a lack of real-world data about Nd:YAG-caps use. Purpose This study’s objectives were to estimate Nd:YAG-caps incidence in France, to describe the patient characteristics, and to analyze the time between surgeries and capsulotomies. Setting: The study was based on data extracted from the EGB database, a 1/97th sample representative of the French population. Design: observational, retrospective, cohort study using national claims data. Methods French adult patients who underwent Nd:YAG-caps between 2014 and 2017 were selected. Main outcomes were the number of patients and procedures performed and the risk factors associated with early Nd:YAG-caps. Results: During the study period, Nd:YAG-caps were performed in 8,425 patients accounting for 10,774 procedures. The extrapolation to the French population led to estimate that 253.103 patients had Nd:YAG-caps, representing 312.103 procedures in 2017. The mean age at Nd:YAG-caps was 75.1 (± 10.2) years. About 36% of patients presented at least one ocular comorbidity. Nd:YAG-caps was performed within 2 years after surgery in 33.0% of patients and within one year in 9.8% of patients. Patients with Nd:YAG-caps within the first year (OR CI95 0.721 [0.673–0.772]) or in the first two years (OR CI95 0.721 [0.673–0.772]) were younger than patients with later Nd:YAG-caps and had a more frequent history of treated ocular diseases (OR 1.516 and 1.178, respectively). Conclusions This study brought new real-world and large-scale data regarding Nd:YAG-caps use and gave an updated insight into the patients’ characteristics.

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology,General Medicine

Reference39 articles.

1. Caisse Nationale d’Assurance Maladie. Actes techniques de la CCAM en 2021 | L’Assurance Maladie. https://assurance-maladie.ameli.fr/etudes-et-donnees/actes-techniques-ccam-2021. Accessed 5 Oct 2022.

2. Agence Technique de l’Information sur l’Hospitalisation. Open CCAM 2021 | Stats ATIH. https://www.scansante.fr/mco-actes-ccam-par-etablissements/open-ccam-2021. Accessed 5 Oct 2022.

3. Ayed T, Rannen R, Naili K, Sokkah M, Gabsi S. [Risk factors for secondary cataract: a case-control study with multivariate analysis]. J Fr Ophtalmol. 2002;25:615–20.

4. Benzerroug M, Milazzo S. La cataracte secondaire. EMC Ophtalmologie. 2014;11.

5. Royal College of Ophthalmologists. RCOphth NOD PCO Report 2021.pdf. https://www.nodaudit.org.uk/u/docs/20/rijbxkcubs/RCOphth%20NOD%20PCO%20Report%202021.pdf. Accessed 5 Dec 2022.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3